**Oral Formulation**

- If the patient has hypersensitivity to verapamil or any component in the verapamil formulation (immediate-release or extended-release)

- Severe dysfunction of the left ventricle

- Severe hypotension, defined as a systolic blood pressure reading of less than 90 mmHg or cardiogenic shock (except in patients with a functioning artificial ventricular pacemaker)

- Sick sinus syndrome and second or third-degree atrioventricular block (the main exception being in patients who have a functioning artificial ventricular pacemaker)

- Atrial flutter/fibrillation with an accessory bypass tract (Lown-Ganong-Levine syndrome, Wolff-Parkinson-White [WPW] syndrome)

**Intravenous Formulation**

- Severe heart failure (unless the heart failure results from a supraventricular tachycardia responsive to verapamil)

- Concomitant use of intravenousÂ beta-blockers